相似文献
1
"Pharmacogenetics of Cancer" - special issue.
Cancer Drug Resist. 2020 Feb 20;3(2):225-231. doi: 10.20517/cdr.2020.10. eCollection 2020.
2
PREFACE for the special issue of xenobiotica on "pharmacogenetics of drug metabolism".
Xenobiotica. 2020 Jan;50(1):1-2. doi: 10.1080/00498254.2019.1682716. Epub 2019 Oct 28.
3
Pharmacogenetics and breast cancer management: current status and perspectives.
Expert Opin Drug Metab Toxicol. 2015 May;11(5):719-29. doi: 10.1517/17425255.2015.1008447. Epub 2015 Feb 18.
4
An interview with Pharmacogenomics for the breast cancer special focus issue.
Pharmacogenomics. 2012 Apr;13(6):655-8. doi: 10.2217/pgs.12.33.
5
Pharmacogenetics of stomach cancer.
Suppl Tumori. 2003 Sep-Oct;2(5):S19-22.
6
Pharmacogenetics in Psychiatry.
Pharmacopsychiatry. 2020 Jul;53(4):153-154. doi: 10.1055/a-1212-1101. Epub 2020 Jul 27.
7
Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?
Expert Rev Anticancer Ther. 2021 Feb;21(2):149-163. doi: 10.1080/14737140.2021.1843430. Epub 2020 Nov 16.
8
Special Issue on Pharmacogenetics is dedicated to the memory of Professor Robert W Kerwin.
J Psychopharmacol. 2012 Mar;26(3):333-428.
9
An interview with Pharmacogenomics for the breast cancer special focus issue.
Pharmacogenomics. 2012 Apr;13(6):651-4. doi: 10.2217/pgs.12.32.
10
Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance.
Cancer Cell. 2004 Aug;6(2):105-7. doi: 10.1016/j.ccr.2004.08.003.
引用本文的文献
1
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma.
Cancers (Basel). 2023 May 13;15(10):2753. doi: 10.3390/cancers15102753.
本文引用的文献
1
Pharmacogenetics of thiopurines.
Cancer Drug Resist. 2019 Jun 19;2(2):256-270. doi: 10.20517/cdr.2019.004. eCollection 2019.
2
Pharmacogenetic and pharmacogenomic discovery strategies.
Cancer Drug Resist. 2019 Jun 19;2(2):225-241. doi: 10.20517/cdr.2018.008. eCollection 2019.
3
Emerging targets in cancer drug resistance.
Cancer Drug Resist. 2019 Jun 19;2(2):161-177. doi: 10.20517/cdr.2018.27. eCollection 2019.
4
Pharmacogenetics of asparaginase in acute lymphoblastic leukemia.
Cancer Drug Resist. 2019 Jun 19;2(2):242-255. doi: 10.20517/cdr.2018.24. eCollection 2019.
5
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Cancer Drug Resist. 2019 Sep 19;2(3):680-709. doi: 10.20517/cdr.2019.006. eCollection 2019.
6
Insights into breast cancer phenotying through molecular omics approaches and therapy response.
Cancer Drug Resist. 2019 Sep 19;2(3):527-538. doi: 10.20517/cdr.2018.009. eCollection 2019.
7
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.
Cancer Drug Resist. 2019 Sep 19;2(3):665-679. doi: 10.20517/cdr.2019.002. eCollection 2019.
8
Somatic pharmacogenomics of gastrointestinal stromal tumor.
Cancer Drug Resist. 2019 Mar 19;2(1):107-115. doi: 10.20517/cdr.2019.02. eCollection 2019.
9
Germline variants in cancer therapy.
Cancer Drug Resist. 2019 Mar 19;2(1):18-30. doi: 10.20517/cdr.2019.05. eCollection 2019.
10
Pharmacogenetics of anticancer monoclonal antibodies.
Cancer Drug Resist. 2019 Mar 19;2(1):69-81. doi: 10.20517/cdr.2018.20. eCollection 2019.
Zotero 插件